UTP20

Across TCGA pan-cancer cohorts, UTP20 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated UTP20 data layer compared with 26 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher UTP20 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated UTP20 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, LSCC, and HNSC are the cancer types where UTP20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.354	0.762	<.001	76	view →
LSCC	OS	Median	II,III,IV	0.928	0.564	<.001	37	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	19	view →
LUAD	OS	Median	III,IV	0.911	0.325	.013	15	view →
GBM	OS	Tertile	All	0.673	0.482	.024	5	view →
PDAC	OS	Quartile	II,III,IV	0.320	0.571	.027	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

UTP20–CCRCC (DFS)

Open the CCRCC breakdown →